



DB085: DBC2 (C20)

Background:

Representational difference analysis (RDA) was the technique used to map a region on human chromosome 8p21 that contained a homozygous deletion several of the breast cancer specimens studied (1). The mapping of this region led to the identification of a gene with somatic mutations in breast cancer cells (1). This expression of this gene DBC2 (deleted in breast cancer) was extinguished in about half of the breast and lung cancer specimens that were examined, making it a good tumor suppressor candidate (1). The functional analysis of DBC2 found that expression of DBC2 in breast cancer cells missing DBC2 transcripts resulted growth inhibition (1).

Origin:

DBC2 (C20) is provided as an affinity purified rabbit polyclonal antibody, raised against a peptide mapping to the amino terminal domain of human DBC2.

Product Details:

Each vial contains 200 µg/ml of affinity purified rabbit IgG, DBC2 (C20) DB085, in 1 ml PBS containing 0.1 % sodium azide and 0.2% gelatin.

Competition Studies:

A blocking peptide is also available, DB085P, for use in competition studies. Each vial contains 100 µg of peptide in 0.5 ml PBS with 0.1% sodium azide and 100 µg BSA.

Specificity:

DBC2 (C20) is recommended to detect mouse, rat and human DBC2 by western blotting. Recommended western blotting starting dilution 1:200.

Storage:

Store this product at 4° C, do not freeze. The product is stable for one year from the date of shipment.

References:

1. Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, Rodgers L, Walsh T, Welch P, King MC, Wigler MH. 2002. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. PNAS USA 99(21):13647-13652.